MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company develops MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent in Phase 2b/3 clinical trial for treating neurological and other disorders, such as progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. It is also developing MN-001 (tipelukast), an orally bioavailable small molecule compound in Phase 2 clinical trial to treat fibrotic and other metabolic disorders, including nonalcoholic fatty liver disease and hypertriglycedemia. The company has a license agreement with Kyorin Pharmaceuticals for the development and commercialization of MN-166 and MN-001. MediciNova, Inc. was incorporated in 2000 and is headquartered in La Jolla, California.

Current Quarter	$-0.06	Next Quarter	$-0.06
Current Year	$-0.26	Next Year	$-0.43
QoQ Growth	+0.0%	YoY Growth	-65.4%
3Y EPS CAGR	-3.1%	Target Price	$9.00
Consensus	Buy	Upside	+520.7%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	MNOV	$1.45	+2.11%	18.59K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	MNOV	$1.45	+2.1%	18.59K
3
4
5
6

MNOV

MNOV

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get MediciNova Inc. Data in Excel

Get MediciNova Inc. Data in Excel